U.S. regulators said certain promotional materials for Johnson & Johnson’s epilepsy drug Topamax fail to disclose serious risks linked to the medicine and asked the company to immediately cease using them. In a warning letter to J&J unit Ortho-McNeil dated Sept. 15 and posted on the Food and Drug Administration Web site on Wednesday, the agency said the promotional material was missing information about serious side effects associated with Topamax, including hyperthermia and insufficient sweat production.
